Immutep reports encouraging EFTISARC-NEO Phase II sarcoma survival data

Immutep reported encouraging survival data from its EFTISARC-NEO Phase II sarcoma trial. Efti plus KEYTRUDA and radiotherapy showed 81.1% 12-month disease-free survival, 94.1% local recurrence-free survival and 86.2% distant metastasis-free survival in 38 patients.

Detected & updated continuously · Source: Nebula